The US FDA (Food and Drug Administration) recommended a pause in the use of the Johnson & Johnson single-dose coronavirus vaccine after six patients in the U.S. developed a rare blood clot disorder after receiving it.
All six cases were in women aged between 18 and 48, with symptoms appearing six to 13 days after vaccination.
One patient died from blood clotting complications, while another is in a critical condition, the FDA’s Peter Marks confirmed.
The decision creates a slow down in the race towards the fight against the coronavirus.’
In a statement they said, ‘We are aware of an extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received our Covid-19 vaccine, The United States Centers for Disease Control (CDC) and Food and Drug Administration (FDA) are reviewing data involving six reported US cases out of more than 6.8 million doses administered. Out of an abundance of caution, the CDC and FDA have recommended a pause in the use of our vaccine.’
The company decided to create the delay to buy time to review the case with European health authorities. It also confessed to working closely with medical and health authorities to convey the right news to the public.
The blood clots require unique treatment that has been offered for the proper management and recognition by those who have already received the vaccine.
People who have received the Johnson and Johnson Covid-19 vaccine and develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their healthcare provider.